title: Persistent fibrosis in the liver of choline-deficient and iron-supplemented L-amino acid-defined diet-induced nonalcoholic steatohepatitis rat due to continuing oxidative stress after choline supplementation.
abstract: Nonalcoholic steatohepatitis (NASH) is characterized by combined pathology of steatosis, lobular inflammation, fibrosis, and hepatocellular degeneration, with systemic symptoms of diabetes or hyperlipidemia, all in the absence of alcohol abuse. Given the therapeutic importance and conflicting findings regarding the potential for healing the histopathologic features of NASH in humans, particularly fibrosis, we investigated the reversibility of NASH-related findings in Wistar rats fed a choline-deficient and iron-supplemented l-amino acid-defined (CDAA) diet for 12weeks, with a recovery period of 7weeks, during which the diets were switched to a choline-sufficient and iron-supplemented l-amino acid-defined (CSAA) one. Analysis showed that steatosis and inflammation were significantly resolved by the end of the recovery period, along with decreases in AST and ALT activities within 4weeks. In contrast, fibrosis remained even after the recovery period, to an extent similar to that in continuously CDAA-fed animals. Real-time reverse transcriptase-polymerase chain reaction, Western blot, and immunohistochemical investigations revealed that expression of some factors indicating oxidative stress (CYP2E1, 4-HNE, and iNOS) were elevated, whereas catalase and SOD1 were decreased, and a hypoxic state and CD34-positive neovascularization were evident even after the recovery period, although the fibrogenesis pathway by activated α-SMA-positive hepatic stellate cells via TGF-β and TIMPs decreased to the CSAA group level. In conclusion, persistent fibrosis was noted after the recovery period of 7weeks, possibly due to sustained hypoxia and oxidative stress supposedly caused by capillarization. Otherwise, histopathological features of steatosis and inflammation, as well as serum AST and ALT activities, were recovered.
authors.affiliation: Drug Safety Research Labs, Astellas Pharma Inc., Osaka 532-8514, Japan. ayano.takeuchi@astellas.com
authors.forename: Ayano
authors.initials: A
authors.lastname: Takeuchi-Yorimoto
authors.forename: Takahisa
authors.initials: T
authors.lastname: Noto
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yamada
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Miyamae
authors.forename: Yuji
authors.initials: Y
authors.lastname: Oishi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Matsumoto
mesh_terms: D000596:Amino Acids / Q000008:administration & dosage* / Q000633:toxicity; D000818:Animals; D002794:Choline / Q000008:administration & dosage*; D002796:Choline Deficiency / Q000188:drug therapy / Q000378:metabolism*; D019587:Dietary Supplements; D005234:Fatty Liver / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D007501:Iron / Q000008:administration & dosage* / Q000633:toxicity*; D008103:Liver Cirrhosis / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000596:Amino Acids; D007501:Iron; D002794:Choline